Tagged with S

Czech Republic Jiří Volf, GM of BB Pharma, explains his motivation behind starting an entrepreneurial journey, the company’s competitive advantage in the face of international and local players, their business strategy in the Czech market and the exciting plans for BB Pharma to expand beyond European frontiers.   We are often approached…

UAE Mundipharma, through its model of independent associated companies, is aiming to take the lead in the Middle East, Turkey & Africa markets through its continuous commitment to improving peoples’ lives. Ashraf Allam, regional VP for the META region, discusses his journey of building Mundipharma’s strong footprint in the region and…

Czech Republic Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s marketing strategy in medical aesthetics, the company’s strongest franchise locally, and the characteristics of the Czech market when it comes…

Sweden As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year presence in the Nordic region and the unparalleled advantages of conducting clinical studies in Sweden.   Sweden has many startups…

Czech Republic Bernard Bauer, CEO and board member at the German-Czech Chamber of Industry and Commerce, discusses the factors that make the German-Czech collaboration such a natural and powerful one, out of which the two countries’ common industrial tradition plays a key role. Furthermore, Bauer assesses the evolution of bilateral trade relations,…

Hungary In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of Health Insurance Fund Management (NEAK), explains, this has already had a significant impact on patient access to innovative new products.…

France These are worrying times for iconic French mid-cap Ipsen. Trials for palovarotene, a treatment for rare bone disorders, have been plagued by setbacks, perhaps contributing to erstwhile CEO David Meek’s decision to quit the firm in December 2019. The company’s share price has since plummeted.   Meek’s resignation to join…

Hungary Tamás Demeter, Country Manager for AOP Orphan shares his insights on the footprint of the company in Hungary, the areas of therapeutic need that AOP caters to, the performance of 2019 and its key achievements, the ecosystem of rare diseases in Hungary, and patient awareness while highlighting the role of…

Gilead Pavel Brezina, who led the establishment of Gilead’s affiliate in the Czech Republic and Slovakia seven years ago, shares the amazing journey of bringing the company’s life-saving treatments for HIV infection and chronic hepatitis C (CHC) to patients and presents the way the affiliate collaborates with authorities and associations to…

Hungary Katinka Zinnemers, managing director of Abacus Medicine, highlights the company’s mission to increase access to medicines for all patients and its commitment to building trust with authorities as it enters into the arena of parallel imports.     As a parallel trade company, we must be compliant in the same manner…

CEE Ingrid Šmerdová, General Manager of Adamed in the Czech Republic and Slovakia, shares her thoughts about the role their future product pipeline will have in continuing to build the company’s growth within the Czech generics market. Moreover, Šmerdová portrays Adamed’s family-oriented approach as a key differentiator within the pharmaceutical industry…

Hungary Csaba Kis, CEO of Qualiskills, shares his insights on the packaging capabilities of the company, its sustainable competitive advantage, the impact of the European serialization guidelines, and the company’s strategic objectives for the future.   With the Falsified Medicines Directive of February 9, almost all drugs within the EU had…